Abbott Reveals CE Mark Approval For XIENCE Xpedition Everolimus Eluting ... NASDAQ (RTTNews.com) - Global health care company Abbott (ABT) Monday announced that its novel XIENCE Xpedition Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease has received CE mark in Europe. The company stated that ... |
